RECENTLY PUBLISHED 

The American Heart Association/American Stroke Association have updated guidelines on secondary stroke prevention, with a recommendation for PFO closure in selected patients. MAT-2107557 v1.0| Item approved for Global OUS use only.

 

 AbbottAbbott
INT

Amplatzer™ PFO Occluder

A Turning Point
for PFO Closure

The Landmark RESPECT Trial

The RESPECT Trial1 offers conclusive evidence that using the Amplatzer™ PFO Occluder to close the patent foramen ovale (PFO) in patients with cryptogenic stroke, is more beneficial than medical therapy in preventing recurrent stroke.

  • Mohammed Mojadidi
  • Mohammed Mojadidi, et al.4

    More Robust Benefit with Amplatzer PFO

    The meta-analysis confirmed that “PFO closure was superior to medical therapy for secondary prevention of stroke…with a more robust benefit when the Amplatzer PFO Occluder from PC and RESPECT trials was used.”

More Patients, Longer Follow-Up

The RESPECT trial stands apart among PFO closure studies, since it's the largest clinical trial with the most extensive follow-up, spanning 13 years overall. The 980 enrolled patients were followed for a median of 5.9 years. Researchers ultimately collected over 5,810 patient years of data1—2 times more than in other PFO trials.

Very Low Rate of Adverse Events

RESPECT data revealed low rates of serious adverse events:1

0%

DEVICE EMBOLIZATION

0%

AORTIC EROSION/DISSECTION

0%

DEVICE THROMBUS

Excellent Procedural Results

The RESPECT trial data reveal high rates of technical and procedural success and excellent closure with the study’s highly stringent criteria. At only 6 months, patients also demonstrated freedom from shunt—both at rest and during Valsalva.1

99.1%

TECHNICAL SUCCESS

96.1%

PROCEDURAL SUCCESS

94.2%

EFFECTIVE CLOSURE
(n ≤ 9 bubbles)

Rigorous Design Included Patients on Anticoagulants

Among the study’s inclusion criteria, RESPECT included patients on anticoagulation therapy—which was not true for other PFO trials, REDUCE2 and CLOSE.3 Therefore, the RESPECT trial provides a real world cross section of patients. RESPECT was conducted at 69 centers across the U.S. and Canada.

  • Significantly Less Risk of Recurrent Stroke

    The RESPECT trial further revealed a 62% relative risk reduction for recurrent cryptogenic ischemic stroke with the Amplatzer PFO Occluder vs medical therapy.1

    The RESPECT trial further revealed a 62% relative risk reduction for recurrent cryptogenic ischemic stroke with the Amplatzer PFO Occluder vs medical therapy.1

    In addition, there was a 45% relative risk reduction for any recurrent ischemic stroke over nearly 6 years of follow-up, compared to medical therapy.1
     

    In addition, there was a 45% relative risk reduction for any recurrent ischemic stroke over nearly 6 years of follow-up, compared to medical therapy.1
     

  • Low Rates of Atrial Fibrillation

    The RESPECT trial also revealed low rates of serious atrial fibrillation (AF) with the Amplatzer device, consistent with medical therapy.1 AF rates were somewhat higher in the REDUCE trial,2 which used a different PFO closure device.

    RATE

    (PER 100 PATIENT YEARS)

    		RESPECT1REDUCE2
    Serious AF†/Flutter0.220.65
    Any AF/Flutter0.761.90

    CLOSE trial data are not included since follow-up patient years was not reported.

  • 3 Trials Provide Conclusive Evidence of PFO Closure Superiority over Medical Management

    Three recent trials across the industry provide conclusive evidence that PFO closure is superior to medical management in reducing the risk of recurrent stroke.

     

    RESPECT1

    		REDUCE2

    CLOSE3

    Devices Used100% AmplatzerTM PFO Occluder39% GORE® HELEX®,
    61% GORE® CARDIOFORM    		51% AmplatzerTM PFO Occluder;
    49% approved PFO devices
    Patients980664473
    Follow-Up

    5,810

    (median 5.9 yrs)

    2,232

    (median 3.2 yrs)

    Not Reported

    (median 5.4 yrs)

    Anticoaguant Allowed in Control Group?YesNoNo
    Relative Risk Reduction

    62%

    (Recurrent ischemic stroke of unknown mechanism)

    77%

    (Recurrent ischemic stroke)

    97%

    (Recurrent ischemic stroke)

    Effective Closure

    92%

    Freedom from > 9 bubbles (Evaluated after 6 months)

    94.5%

    Freedom from > 25 bubbles (Evaluated after 12 months)

    		Not Reported

MAT-2010605 v1.0 | Item approved for Global OUS use only.

References

*Rates are calculated based on data in final publication.
† In RESPECT, serious AF was adjudicated by an independent board of physicians. In REDUCE, it was determined by the local investigator.

  1. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377:1022-1032. doi: 10.1056/NEJMoa1610057.
  2. Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377:1033-1042. doi: 10.1056/NEJMoa1707404.
  3. Mas J-L, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377:1011-1021 and supplementary appendix. doi: 10.1056/NEJMoa1705915.
  4. Mojadidi MK, Zaman MO, Elgendy IY, et al. Cryptogenic stroke and patent foramen ovale. J Am Coll Cardiol. 2018;71(9):1035-1043. doi: 10.1016/j.jacc.2017.12.059.
     

GET CLINICAL INSIGHTS

DOWNLOAD

PATIENT EDUCATION

READ MORE

Let’s get in touch!

Contact us

Copyright © 2021 Abbott. Abbott Park, Illinois, U.S.A.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Illustrations are artist's representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

MAT-2000631 v5.0 | Item approved for Global OUS use only.

This site uses cookies to improve your experience.

To find out more please read our Privacy and Cookies policy.

Ok

Sign up

Receive updates from Abbott Structural Heart

Register now

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

International Health Care Professionals U.S. Health Care Professionals

YOU ARE ABOUT TO LEAVE
www.structural­heart­solutions.com

You are now leaving www.structuralheartsolutions.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

OkCancel